Lexicon Pharmaceuticals (LXRX) Net Equity Issued and Repurchased (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 15 years of Net Equity Issued and Repurchased data on file, last reported at $70.0 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $70.0 million in Q1 2026; TTM through Mar 2026 was $70.0 million, a 128.99% increase from a year earlier, with the FY2021 full-year figure at $37.1 million, down 47.0% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $70.0 million, up from -$241.4 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for LXRX reached as high as $241.4 million in Q1 2024 and fell as low as -$241.4 million in Q4 2024.
• Historically, Net Equity Issued and Repurchased has averaged -$2.7 million across 4 years, with a median of -$15000.0 in 2024.
• Across the five-year window, Net Equity Issued and Repurchased sank 24972.82% in 2022 and soared 94.35% in 2024, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$94.3 million in 2022, then tumbled by 47.26% to -$138.8 million in 2023, then sank by 73.89% to -$241.4 million in 2024, then jumped by 128.99% to $70.0 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $70.0 million in Q1 2026, -$241.4 million in Q4 2024, and -$10000.0 in Q3 2024.